Browsing Tag
NYSE
114 posts
Lennar (NYSE: LEN) dips as Q2 profit beat is overshadowed by revenue miss and margin compression
Lennar (LEN) dips as a Q2 profit beat is overshadowed by a revenue miss and margin compression amid high mortgage rates. Read the full executive analysis.
Dana stock slides while Eaton (ETN) rises on $5.1bn powertrain combination
Dana (DAN) will absorb Eaton's mobility unit in a $5.1B Reverse Morris Trust. DAN fell 15 percent as ETN rose. Read the full executive analysis of the deal.
Planet Labs (NYSE: PL) crashes 25% after a record quarter and a 400% run
Planet Labs (NYSE: PL) posted record revenue and big defense wins, then fell 25%. After a 400% run, expectations, not results, became the problem.
Dycom, Vicor, Shoals and Luxfer hit 52-week highs as data center and defense demand surges
AI data center power demand and a rearming defense sector drove Dycom, Vicor, Shoals, and Luxfer to 52-week highs, with Dycom surging 28% on record results. Read more.
Wipro (NSE: WIPRO) buyback at Rs 250 looks like easy money. The acceptance ratio says otherwise
Wipro's â‚ą250 buyback looks like a guaranteed 20 percent. After the acceptance ratio and new buyback tax, retail may keep a fraction of it.
Accenture backs Aera Technology as enterprises race toward autonomous supply chains
Find out how Accenture’s Aera Technology investment could reshape AI-enabled supply chains, decision intelligence and enterprise automation.
Should retail investors buy ING Groep (INGA) at €26 ahead of Q2 2026 results?
ING beat Q1 estimates and launched a €1bn buyback. But a €94m Iran war credit overlay is the line analysts are not pricing.
Equinor locks in 5-year German gas supply via Eneco’s LichtBlick as Berlin’s Norwegian dependence deepens
Equinor signs 5-year gas deal with Eneco's LichtBlick, supplying low-emission Norwegian gas to Germany through 2030 as Berlin's NCS dependence deepens. Read more.
Lilly (LLY) acquires Engage Biologics for up to $202m to advance non-viral DNA delivery platform
Eli Lilly (NYSE: LLY) acquires Engage Biologics for up to $202 million, adding the Tethosome non-viral DNA platform to its genetic medicines portfolio. Read more.
Magnum Ice Cream (NYSE: MICC) jumps 10.9% on Blackstone and CD&R takeover talk just five months after the Unilever spinoff
Magnum spun out of Unilever at 7.8 billion euros. Froneri sold at 15 billion. Blackstone and CD&R are watching. The summer ice cream season decides the bid.